AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31270297 — intervention group
Group type: EXPERIMENTAL
Intervention: APC combined with ESU
Number of subjects: 70
Study 31270297 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 70
Study 31270297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleurodesis
Number of subjects: 70
Study 27893491 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE and low-molecular-weight heparins (LMWH)
Number of subjects: 40
Study 27893491 — intervention group
Group type: COMPARATOR
Intervention: TACE only
Number of subjects: 40
Study 25722381 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg orally once daily)
Number of subjects: 129
Study 25722381 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 i.v. every 3 weeks)
Number of subjects: 129
Study 23683456 — intervention group
Group type: EXPERIMENTAL
Intervention: Category group (CT) - listened to a tape containing five animal names
Number of subjects: 60
Study 23683456 — intervention group
Group type: EXPERIMENTAL
Intervention: Word recognition group (WM) - listened to a tape containing five intermediate-frequency words
Number of subjects: 60
Study 23683456 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - listened to sea sounds
Number of subjects: 60
Study 21235774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Cognitive Therapy (M-CT) in addition to treatment as usual (TAU)
Number of subjects: 268
Study 21235774 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 268
Study 19586231 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment, abstinence-contingent housing, and vocational training (various combinations)
Number of subjects: 543
Study 17584549 — intervention group
Group type: EXPERIMENTAL
Intervention: High-bolus-dose tirofiban (25 microg/kg over 3 minutes, followed by 0.15 microg/kg per minute for 18 to 24 hours)
Number of subjects: 0
Study 17584549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 0
Study 17584549 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 0
Study 17584549 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 0
Study 15685894 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic biopsy gun (Asecut)
Number of subjects: 215
Study 15685894 — intervention group
Group type: COMPARATOR
Intervention: Standard Tru-Cut needle
Number of subjects: 215
Study 12237625 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal destruction of the endometrium
Number of subjects: 82
Study 12237625 — intervention group
Group type: COMPARATOR
Intervention: Transcervical hysteroscopic endometrial resection
Number of subjects: 82
Study 12237625 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 82
Study 9845793 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound evaluation of hepatic veins and intra and extrahepatic portal vein territories in patients with APP.
Number of subjects: 13
Study 9845793 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound evaluation of hepatic veins and intra and extrahepatic portal vein territories in healthy subjects (control group).
Number of subjects: 13
Study 7865492 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 190
Study 7865492 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 190
Study 7865492 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 190
Study 7865492 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS and metronidazole double therapy
Number of subjects: 190
Study 7865492 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS, metronidazole and amoxicillin triple therapy
Number of subjects: 190
Study 7865492 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradicated group
Number of subjects: 190
Study 7865492 — intervention group
Group type: COMPARATOR
Intervention: H. pylori not eradicated group
Number of subjects: 190
Study 2764657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening reminders
Number of subjects: 62
Study 2764657 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit with feedback
Number of subjects: 62
Study 2764657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 62
Study 2764657 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 62
Study 81218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy and cytoreductive surgery
Number of subjects: 0
Study 30030134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (targeted combination intervention)
Number of subjects: 8231
Study 30030134 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 8231
Study 27354460 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 279
Study 27354460 — intervention group
Group type: COMPARATOR
Intervention: Safety control
Number of subjects: 279
Study 25024716 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐03654764 + fexofenadine
Number of subjects: 64
Study 25024716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine + fexofenadine
Number of subjects: 64
Study 25024716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22219060 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise program (9 exercises for lumbar region, executed daily for 8 minutes)
Number of subjects: 98
Study 22219060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study 20737584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.56 mg/kg i.c.)
Number of subjects: 46
Study 20737584 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (1 mg i.c.)
Number of subjects: 46
Study 20737584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole after Verapamil
Number of subjects: 46
Study 20737584 — intervention group
Group type: COMPARATOR
Intervention: Verapamil after Dipyridamole
Number of subjects: 46
Study 18621929 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) and standard therapy
Number of subjects: 95
Study 18621929 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 95
Study 16418557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex education program (4 sessions over 4 weeks)
Number of subjects: 41
Study 16418557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 13679675 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (300 ml for two weeks)
Number of subjects: 20
Study 13679675 — intervention group
Group type: COMPARATOR
Intervention: White wine (300 ml for two weeks)
Number of subjects: 20
Study 10377645 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) chip with scaling and root planing (SRP)
Number of subjects: 0
Study 10377645 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 0
Study 8777337 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha interferon therapy for 4 months
Number of subjects: 3
Study 1836220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 5 mg, increased to 10 mg if DBP > 95 mmHg, administered orally once daily for 4 weeks
Number of subjects: 17
Study 1836220 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg, increased to 50 mg if DBP > 95 mmHg, administered orally once daily for 4 weeks
Number of subjects: 17
Study 6316670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime treatment
Number of subjects: 153
Study 31562930 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V. House UltraDressing
Number of subjects: 60
Study 31562930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 31562930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29303805 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of short gastric vessels
Number of subjects: 102
Study 29303805 — intervention group
Group type: COMPARATOR
Intervention: Nondivision of short gastric vessels
Number of subjects: 102
Study 27422216 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal immobilization at 20° (group 2)
Number of subjects: 56
Study 27422216 — intervention group
Group type: COMPARATOR
Intervention: Spinal immobilization at 0° (group 1)
Number of subjects: 56
Study 25341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection
Number of subjects: 159
Study 25341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection (first injection)
Number of subjects: 159
Study 25341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection (second injection)
Number of subjects: 159
Study 25341673 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection (third injection)
Number of subjects: 159
Study 25341673 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid and NaCl injections
Number of subjects: 159
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN/ENV 2×10(9) (A)
Number of subjects: 56
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN/ENV 2×10(10) (B)
Number of subjects: 56
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN/ENV 2×10(11) (C)
Number of subjects: 56
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN 1×10(10) (D)
Number of subjects: 56
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN/ENV (A, B, C)
Number of subjects: 56
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN (D)
Number of subjects: 56
Study 22870265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35‐GRIN/ENV and Ad35‐GRIN
Number of subjects: 56
Study 22870265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20220333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus prednisone
Number of subjects: 73
Study 20220333 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus prednisone
Number of subjects: 73
Study 18809799 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for PMR with coronary artery bypass graft
Number of subjects: 54
Study 18809799 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for PMR
Number of subjects: 54
Study 16040637 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE anaesthesia with EVE
Number of subjects: 60
Study 16040637 — intervention group
Group type: COMPARATOR
Intervention: CSE anaesthesia without EVE (NEVE group)
Number of subjects: 60
Study 12392825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (400 mg orally twice daily) and 0.45% saline intravenously
Number of subjects: 121
Study 12392825 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 0.45% saline
Number of subjects: 121
Study 10444731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha fetoprotein testing and ultrasonography
Number of subjects: 9373
Study 10444731 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography alone
Number of subjects: 9373
Study 10444731 — intervention group
Group type: COMPARATOR
Intervention: Alpha fetoprotein test alone
Number of subjects: 9373
Study 8697727 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20dim T lymphocytes
Number of subjects: 41
Study 8697727 — intervention group
Group type: COMPARATOR
Intervention: CD20bright B-cells
Number of subjects: 41
Study 2179754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CS) 5‐8 mg/kg/24 h and warfarin
Number of subjects: 9
Study 2179754 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 9
Study 7152084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrils for the first 2 weeks
Number of subjects: 47
Study 7152084 — intervention group
Group type: COMPARATOR
Intervention: Aludrox tablets for the first 2 weeks
Number of subjects: 47
Study 7152084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrils
Number of subjects: 47
Study 7152084 — intervention group
Group type: COMPARATOR
Intervention: Aludrox tablets
Number of subjects: 47
Study 30975121 — intervention group
Group type: EXPERIMENTAL
Intervention: Active or passive smoking (defined as 1 cigarette or more per day for up to 1 year)
Number of subjects: 55806
Study 30975121 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive plus active smoking
Number of subjects: 55806
Study 30975121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined smoking with the highest exposure dose
Number of subjects: 55806
Study 30975121 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of smoking exposure
Number of subjects: 55806
Study 29171379 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (n=249)
Number of subjects: 485
Study 29171379 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (n=198)
Number of subjects: 485
Study 29171379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=236)
Number of subjects: 485
Study 29171379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=217)
Number of subjects: 485
Study 26276749 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy bread (SB)
Number of subjects: 32
Study 26276749 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-almond bread (SAB)
Number of subjects: 32
Study 26276749 — intervention group
Group type: COMPARATOR
Intervention: Soy bread (SB) and Soy-almond bread (SAB)
Number of subjects: 32
Study 23649573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step self-etch adhesive (SEA)
Number of subjects: 48
Study 23649573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step self-etch adhesive (SEA)
Number of subjects: 48
Study 21328434 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI titration protocol (argatroban or bivalirudin)
Number of subjects: 130
Study 19144734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin kernel flour-enriched bread
Number of subjects: 88
Study 19144734 — intervention group
Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 88
Study 20554370 — intervention group
Group type: EXPERIMENTAL
Intervention: aceclofenac 100mg-drotaverine 80 mg b.i.d
Number of subjects: 200
Study 20554370 — intervention group
Group type: COMPARATOR
Intervention: aceclofenac 100mg alone b.i.d
Number of subjects: 200
Study 16118805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell support (HDC)
Number of subjects: 246
Study 16118805 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose chemotherapy (IDC)
Number of subjects: 246
Study 11772910 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glyburide orally
Number of subjects: 16
Study 11772910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10189518 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of nimodipine
Number of subjects: 5
Study 10189518 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of nimodipine
Number of subjects: 5
Study 10189518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study 7755126 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine retreatment
Number of subjects: 12
Study 7755126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2182437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (including doxorubicin intensification with or without asparaginase)
Number of subjects: 553
Study 2182437 — intervention group
Group type: COMPARATOR
Intervention: Less intensive chemotherapy
Number of subjects: 553
Study 394274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltarol)
Number of subjects: 940
Study 30204768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 141
Study 30204768 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 141
Study 30204768 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 141
Study 27424036 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 2.5-60 mg daily for 7 days
Number of subjects: 37
Study 27424036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 25528350 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sedation supplemented with pain management during mechanical ventilation
Number of subjects: 700
Study 25528350 — intervention group
Group type: COMPARATOR
Intervention: Sedation with a daily wake-up trial
Number of subjects: 700
Study 22500844 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day plus Calcium 1000 mg/day and Vitamin D 100000 IU/month for 6 months
Number of subjects: 100
Study 22500844 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1500 mg/day
Number of subjects: 100
Study 19937996 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared-parameter models for incomplete longitudinal outcomes
Number of subjects: 0
Study 18562162 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-titrated beta-blocker dosing regimen
Number of subjects: 64
Study 18562162 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose beta-blocker dosing regimen
Number of subjects: 64
Study 16021543 — intervention group
Group type: COMPARATOR
Intervention: Conventional full spine radiographs
Number of subjects: 21
Study 16021543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic scanning method
Number of subjects: 21
Study 11949901 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity principle in language learning
Number of subjects: 96
Study 10369504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention, reducing fat intake to 20% of energy, with support from a nutritionist.
Number of subjects: 2208
Study 10369504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 2208
Study 10369504 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2208
Study 7572830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 150
Study 7572830 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 150
Study 2206816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl alcohol swab
Number of subjects: 20
Study 2206816 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol swab
Number of subjects: 20
Study 2206816 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic cetrimide/chlorhexidine swab
Number of subjects: 20
Study 7016802 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 33
Study 7016802 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 33
Study 7016802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30663168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Number of subjects: 31
Study 30474011 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 120 seconds
Number of subjects: 100
Study 30474011 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) within less than 30 seconds
Number of subjects: 100
Study 26014600 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a‐tDCS) during cognitive training
Number of subjects: 20
Study 26014600 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS during cognitive training
Number of subjects: 20
Study 24380397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) with tenofovir/emtricitabine
Number of subjects: 50
Study 24380397 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) with tenofovir/emtricitabine
Number of subjects: 50
Study 24380397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LPV/r and EFV
Number of subjects: 50
Study 21997432 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal appendectomy (TVA)
Number of subjects: 42
Study 21997432 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 42
Study 19267384 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-support intervention for Black women with breast cancer, including in-person sessions, communication skills training, and sharing personal stories
Number of subjects: 34
Study 17609401 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (administered every 14 days for 12 weeks)
Number of subjects: 10
Study 17609401 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy females)
Number of subjects: 10
Study 17609401 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 10
Study 16215191 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace fundamentals program (skills training)
Number of subjects: 35
Study 16215191 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 35
Study 11247010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting hand splints
Number of subjects: 6
Study 11247010 — intervention group
Group type: EXPERIMENTAL
Intervention: Light tech augmentative communication systems (voice-output devices and symbols)
Number of subjects: 6
Study 11247010 — intervention group
Group type: EXPERIMENTAL
Intervention: Very basic parent training
Number of subjects: 6
Study 11247010 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar storybook reading
Number of subjects: 6
Study 11247010 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar storybook reading
Number of subjects: 6
Study 9599853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help booklet with midwife counselling
Number of subjects: 336
Study 9599853 — intervention group
Group type: EXPERIMENTAL
Intervention: New magazine-style smoking cessation booklet
Number of subjects: 336
Study 9599853 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 336
Study 7974298 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol 75% in eucalyptus oil
Number of subjects: 20
Study 7974298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pine oil or air)
Number of subjects: 20